These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Birkeland SA; Hamilton-Dutoit S; Bendtzen K Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802 [TBL] [Abstract][Full Text] [Related]
7. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720 [TBL] [Abstract][Full Text] [Related]
8. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. Wasson S; Zafar MN; Best J; Reddy HK J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222 [TBL] [Abstract][Full Text] [Related]
9. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. Caillard S; Lachat V; Moulin B Transpl Int; 2000; 13 Suppl 1():S388-93. PubMed ID: 11112039 [TBL] [Abstract][Full Text] [Related]
10. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study. Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682 [TBL] [Abstract][Full Text] [Related]
11. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes. Pan K; Franke AJ; Skelton WP; Bishnoi R; Shah C; Dang NH; Alquadan K Leuk Lymphoma; 2021 May; 62(5):1123-1128. PubMed ID: 33327817 [TBL] [Abstract][Full Text] [Related]
12. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study. Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725 [TBL] [Abstract][Full Text] [Related]
13. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience. Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963 [TBL] [Abstract][Full Text] [Related]
14. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193 [TBL] [Abstract][Full Text] [Related]
15. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases]. Chen DB; Wang Y; Song QJ; Shen DH Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829 [TBL] [Abstract][Full Text] [Related]
16. Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611 [TBL] [Abstract][Full Text] [Related]